Show simple item record

dc.contributor.authorvan Capelleveen, Julian C
dc.contributor.authorLee, Sang-Rok
dc.contributor.authorVerbeek, Rutger
dc.contributor.authorKastelein, John JP
dc.contributor.authorWareham, Nicholas
dc.contributor.authorStroes, Erik SG
dc.contributor.authorHovingh, G Kees
dc.contributor.authorKhaw, Kay-Tee
dc.contributor.authorBoekholdt, S Matthijs
dc.contributor.authorWitztum, Joseph L
dc.contributor.authorTsimikas, Sotirios
dc.date.accessioned2019-07-01T23:30:19Z
dc.date.available2019-07-01T23:30:19Z
dc.date.issued2018-11
dc.identifier.issn1933-2874
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/294244
dc.description.abstractBACKGROUND: Plasma apolipoprotein C-III (apoC-III) levels are associated with coronary artery disease (CAD) risk. OBJECTIVE: To assess whether lipoprotein-associated apoC-III levels predict risk of CAD events. METHODS: apoC-III associated with apoB, apoAI, and Lp(a) (apoCIII-apoB, apoCIII-apoAI, and apoCIII-Lp(a), respectively) were measured using high-throughput chemiluminescent enzyme-linked immunoassays in 2711 subjects (1879 controls and 832 cases with CAD) in the European Prospective Investigation into Cancer and Nutrition-Norfolk prospective population study with 7.4 years of follow-up. These measures were correlated with a variety of lipid measurements and the presence of CAD. The indices of "total apoCIII-apoB" and "total apoCIII-apoAI" were derived by multiplying plasma apoB and apoAI, respectively. RESULTS: apoCIII-apoB (P = .001), apoCIII-Lp(a) (P < .001), apoCIII-apoAI (P = .005) were higher in cases vs controls; tended to correlate positively with body mass index, hsCRP, apoC-III, low-density lipoprotein (LDL) cholesterol, triglycerides, remnant cholesterol, very low density lipoprotein, LDL and high-density lipoprotein particle number and very low density lipoprotein size; but negatively with LDL and high-density lipoprotein particle size (P < .001 for all). apoCIII-apoB, apoCIII-apoAI, apoCIII-Lp(a), total apoCIII-Lp(a), and total apoCIII-apoB were predictors of CAD after adjustment of age, sex, body mass index, smoking, diabetes, hypertensive and lipid-lowering drug use, but they lost their significance after further adjustment of lipid and lipoprotein variables. CONCLUSIONS: This study suggests that enzyme-linked immunoassay-measured lipoprotein-associated apoC-III markers reflect atherogenic lipid particles but do not independently predict risk of CAD events.
dc.format.mediumPrint-Electronic
dc.languageeng
dc.publisherElsevier BV
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectHumans
dc.subjectApolipoprotein A-I
dc.subjectRisk Factors
dc.subjectFollow-Up Studies
dc.subjectProspective Studies
dc.subjectAged
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectMale
dc.subjectApolipoprotein B-100
dc.subjectApolipoprotein C-III
dc.subjectCoronary Artery Disease
dc.titleRelationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: The EPIC-Norfolk prospective population study.
dc.typeArticle
prism.endingPage1501.e11
prism.issueIdentifier6
prism.publicationDate2018
prism.publicationNameJ Clin Lipidol
prism.startingPage1493
prism.volume12
dc.identifier.doi10.17863/CAM.41343
dcterms.dateAccepted2018-08-26
rioxxterms.versionofrecord10.1016/j.jacl.2018.08.010
rioxxterms.versionAM
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2018-11
dc.contributor.orcidWareham, Nicholas [0000-0003-1422-2993]
dc.identifier.eissn1876-4789
rioxxterms.typeJournal Article/Review
pubs.funder-project-idMedical Research Council (MC_UU_12015/1)
pubs.funder-project-idDepartment of Health (via National Institute for Health Research (NIHR)) (NF-SI-0617-10149)
pubs.funder-project-idDepartment of Health (via National Institute for Health Research (NIHR)) (NF-SI-0512-10135)
pubs.funder-project-idMedical Research Council (G0401527)
pubs.funder-project-idMedical Research Council (G1000143)
pubs.funder-project-idMedical Research Council (MR/N003284/1)
rioxxterms.freetoread.startdate2019-11-30


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's licence is described as Attribution-NonCommercial-NoDerivatives 4.0 International